ClinicalTrials.gg
RecruitingNCT06294652Updated Apr 10, 2025

AGMT Austrian Lymphoma Registry

An observational study in Lymphoma, sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie · Observational

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
4,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Lymphoma with a site in Austria — 2 open to participants now, 8 under way, 5 of them phase 3. Lymphoma · Austria.

Started
2024
with 1 other
Observational
5 of 29
2 open now
Registered
28th of 29
by date
Lead sponsor
1 of 29
Arbeitsgemeinschaft medikamentoese Tumortherapie

Among the 29 studies in Lymphoma with a site in Austria, this one is one of 2 that started in 2024, is one of 5 observational ones, and was the 28th registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

2 of the 29 studies in Lymphoma with a site in Austria are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Lymphoma with a site in Austria, or all of them as a file.
02

Study summary

Lymphomas are a group of cancers that originate in the lymphatic system, a key component of the immune system. They can be broadly categorized into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

There are different subtypes of HL, including classical Hodgkin lymphoma (cHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The subtypes of cHL include nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted.

Non-Hodgkin lymphomas are more diverse and comprise a wide range of subtypes, each with distinct genetic, molecular, and clinical features. Common subtypes of NHL include Diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma (FL), Mantle cell lymphoma (MCL), Chronic lymphocytic leukemia (CLL), myeloma, and other rarer subgroups.

Many of these diseases typically present with lymph node enlargement, bone marrow infiltration, general and lymphoma subtype specific symptoms and laboratory abnormalities.

Novel agents have improved the prognosis of high-risk lymphoma patients in the front-line and relapsed setting and more accurate prognostic tools enable less intensive treatment for low-risk patients, while maintaining their good prognosis.

Lymphoma disease have not been systematically assessed in Austria to date. This medical registry of the AGMT is thus the first Austrian-wide standardized documentation of epidemiology, clinical course and molecular and other biologic data of this disease. As lymphomas are a very heterogeneous group, not all subtypes will always be documented simultaneously in this registry. Which lymphoma subtype is to be documented can change over time, depending on which clinical question is currently in focus.

Read the detailed description

This registry is designed as international multicenter observational cohort of patients with lymphoma. Information on patient´s clinical presentation, tests, diagnosis, and treatment will be obtained through extraction of data from existing patient medical charts. Longitudinal follow-up data, including survival and tumor progression, will also be extracted from patient medical charts. This patient follow-up data will be obtained until patient death or loss to follow-up.

For documentation in the registry, no further diagnostic or therapeutic measures are required than those already necessary in general. Participation in the registry must not interfere with treatment routines. Only routine data, which has already been recorded in the patient's medical chart, is transferred to the electronic Case Report Forms (eCRF). To maintain patient confidentiality, each patient will be assigned a unique patient identifying number upon enrollment; this number will accompany the patient's medical and other registry information throughout the lifetime of the registry.

A written consent must be obtained prior to the input of data. No informed consent is required from deceased patients.

03

Conditions studied

  • Lymphoma

Browse trials for

Keywords

  • Lymphoma
  • Diffuse large B-cel lymphoma (DLBCL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Interested sites that treat patients in this indication will be invited to participate in this registry.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The registry will include patients ≥ 18 years with lymphoma.

Exclusion criteria

Exclusion Criteria:

  • There are no specific exclusion criteria.
05

Study design

Observational model
Other
Time perspective
Other
Enrollment
4,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. General Characteristics

    To describe general characteristics of lymphoma patients

    Time frame: 10 years

  2. Genetic Profiling

    To describe genetic risk profiles

    Time frame: 10 years

  3. Proportion of lymphoma patients in Austria that require treatment

    To describe the proportion of lymphoma patients in Austria that require treatment

    Time frame: 10 years

  4. Proportion of lymphoma patients in Austria under active surveillance

    To describe the proportion of lymphoma patients in Austria under active surveillance

    Time frame: 10 years

  5. Number of patients with concomitant diseases

    To describe concomitant diseases at diagnosis of lymphoma

    Time frame: 10 years

  6. Number of treatment and outcome of treatment

    To describe treatment and outcome of treatment, among them * historical standard with immunochemotherapy * cellular therapies (e.g. Car-T cells) * novel immunotherapies such as bispecific antibodies * continuous treatment or an induction/maintenance approach * sequence of use of various treatments * treatment duration * treatment adjustments * frequency and degree of response

    Time frame: 10 years

  7. Patient Outcome

    To describe patient's outcome

    Time frame: 10 years

  8. Toxicities

    To describe toxicity with a focus on immunological mediated side effects of treatment (e.g. Cytokine release syndrome (CRS), Immune effector cell-associated neurotoxicity syndrome (ICAN) etc.)

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
  • Universitätsklinik für Innere Medizin III, PMU Salzburg
    Salzburg, 5020, Austria
    Recruiting
    • Richard Greil, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2033, 118 months after the start.

Of 141 non-industry observational studies under Lymphoma, half reached primary completion within 90 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 269. This study's planned 118 months is above that.

Counting every sponsor, half of 160 studies reached it within 82 months; a quarter within 39 and three quarters within 269.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2024
First posted
Mar 5, 2024
StartActual
Feb 27, 2024
Primary completionEst.
Dec 31, 2033
CompletionEst.
Dec 31, 2033
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06294652
Lead sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Responsible party
Sponsor
First posted
Mar 5, 2024
Start date
Feb 27, 2024
Primary completion
Dec 31, 2033 (estimated)
Completion
Dec 31, 2033 (estimated)
Last update
Apr 10, 2025

Study contacts

Daniela Wolkersdorfer, Dr.
Contact
office@agmt.at
+436626404412
Richard Greil, MD
principal investigator · Department of Internal Medicine III, Paracelsus Medical University Salzburg, Salzburg, Austria

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion